Synthesis and Preclinical Evaluation of [Methylpiperazine-(11)C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase

[Image: see text] Brigatinib, a tyrosine kinase inhibitor (TKI) with specificity for gene rearranged anaplastic lymphoma kinase (ALK), such as the EML4–ALK, has shown a potential to inhibit mutated epidermal growth factor receptor (EGFR). In this study, N-desmethyl brigatinib was successfully synthe...

Descripción completa

Detalles Bibliográficos
Autores principales: Högnäsbacka, Antonia A., Poot, Alex J., Kooijman, Esther, Schuit, Robert C., Schreurs, Maxime, Verlaan, Mariska, Beaino, Wissam, van Dongen, Guus A. M. S., Vugts, Danielle J., Windhorst, Albert D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510377/
https://www.ncbi.nlm.nih.gov/pubmed/37647220
http://dx.doi.org/10.1021/acs.jmedchem.3c00722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510377/
https://www.ncbi.nlm.nih.gov/pubmed/37647220
http://dx.doi.org/10.1021/acs.jmedchem.3c00722

Ejemplares similares